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vABSTRACT
Background: Gastrointestinal endoscopy has evolved to become an important
diagnostic, therapeutic as well as surveillance and follow-up modes of  management in
children with diverse gastrointestinal diseases.
There is a paucity of data on gastrointestinal endoscopy in children in the sub- Saharan
African region. The objectives of the study were to describe the socio-demographic
characteristics; presenting symptoms; indications; endoscopic yield; impact of
endoscopy on management; as well as its safety profile and complications. In addition
algorithms for the indications of medical gastrointestinal endoscopy in children were
designed using the results derived from the presenting symptoms and indications for
gastrointestinal endoscopy among the patients.
Methods:
This was a cross sectional descriptive study. Subjects were children < 18 years attending
Red Cross War Memorial Children’s Hospital (RCWMCH) who underwent medical
gastrointestinal endoscopic procedures from  2007 to 2016.
Study ethical approval was obtained from University of Cape Town while written
permission from the RCWMCH Research and Management Committee prior to the
commencement of the study.
Data sheet was used in retrieving relevant patients variables from the hospital’s medical
records and the Division of Paediatric Gastroenterology endoscopy  and laboratory
(histopathology)  databases.
Data was analysed using Stata 13.1. A p- value of less than 0.05 was considered
statistically significant.
Results:
A total of 402 children were studied with 773 endoscopies performed comprising 670
oesophagogastroduodenoscopies (OGD) and 103 colonoscopies.
For OGD: 179 (26.7%), 287(42.8%) and 204 (30.4%) procedures were for diagnostic,
therapeutic and follow – up indications. A total of 78 (10.1%) combined
OGD/colonoscopy were carried out.
Out of 103 total colonoscopies performed,  67 (65.0%),  30(29.1%), and 6 (5.8%), were
for diagnostic, follow – up and therapeutic indications respectively.
vi
Feeding difficulty 112 (25.4%) and rectal bleeding 11 (2.7%) were the main presenting
symptoms for OGD and colonoscopy respectively.
Main diagnostic indications for OGD, combined OGD/colonoscopy and colonoscopy
alone respectively were chronic abdominal pain 51 (12.6%) and probable inflammatory
bowel disease (IBD) 30 (7.5%) and IBD  30 (7.5%). Change  143 (35.6%)/ insertion
87(21.6%) of percutaneous gastrostomy were the most common therapeutic indications
for  OGD and polypectomy 8 (2.7%) for colonoscopy.
Abnormal (positive) macroscopic findings on endoscopy were reported on
79/179(44.1%), 35/68(51.55%), and 46/67(53.7%) of OGD, combined OGD with lower
scope, and colonoscopy alone respectively.
Also,  positive histological findings on OGD, combined OGD with colonoscopy, and
colonoscopy alone were reported in 62/179(34.6%), 34/68(50.0%), and 32/67(47.8%)
respectively.
The overall normal endoscopic findings (both abnormal macroscopic findings on
endoscopy  and histological findings) were 63/179(35.3%) and 25/67(37.3%) for OGD
and colonoscopy while overall diagnostic (endoscopic) yield was 116/179(64.8%) for
OGD and 42/67(62.7%) for colonoscopy respectively.
For OGD the main endoscopic yield reported were gastritis in 50(27.9%)  and
oesophageal varices 31(17.3%) while inflammatory bowel disease (Crohn’s disease
9(13.4%), ulcerative colitis 7(10.4%), juvenile polyps 9(13.4%) and intestinal
tuberculosis 7(10.4%) were observed in colonoscopy respectively.
A significant impact of endoscopy on the management of subjects were recorded in
298(74.1%) (p < 0.001) including  diagnostic (change of medication, addition of new
medication) and therapeutic (insertion/change of PEG; sclerotherapy 29 (9.8%) , band
ligation of oesophageal varices 28 (9.4%), and polypectomy 8(2.7%)).
The overall complication rate was 4.0% (16 patients).
Conclusion:
Feeding difficulty and rectal bleeding were the most common presenting symptoms for
OGD and colonoscopy; with chronic abdominal pain and IBD being the most common
indication for performing OGD and colonoscopy respectively. Therapeutic modalities
of endoscopy performed were PEG insertion/change, polypectomy, sclerotherapy/band
ligation for varices.
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Endoscopic yield was 116/179(64.8%) for OGD and 42/67(62.7%) for colonoscopy
respectively a significant impact of endoscopy on the management of subjects were
recorded in 298(74.1%) (p < 0.001).
No mortalities were recorded following the procedures, however 16(4%) had some
complications.
Use of societal guidelines in selecting children with appropriate indications for
gastrointestinal endoscopy will result in higher diagnostic yield and application of
therapeutic modalities in children with gastrointestinal disorders resulting in significant
impact  on patient’s management  and minimize complications.
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1CHAPTER ONE: INTRODUCTION
1.1 Context
Gastrointestinal endoscopy in children has evolved to become an important diagnostic,
therapeutic and surveillance modes of management in children with gastrointestinal
disorders1 owing to the technological advancements in endoscopy design and its
devices.2,3 Improvements in sedation, anaesthesia4 and skills in monitoring of vital signs
of patients,5 during endoscopic procedures have  added to the increased and safe use of
gastrointestinal endoscopy in children and neonates6 enabling the increase in the
diagnosis of common as well as diagnostic dilemmas in paediatric gastrointestinal
diseases including coeliac disease of which endoscopic biopsy is the gold standard
diagnostic technique,7severe gastro-oesophageal reflux disease,8 eosinophilic
oesophagitis, and inflammatory bowel disease among others.6
Diagnostic and therapeutic modalities of gastrointestinal endoscopy are diverse and
include oesophagogastroduodenoscopy (OGD), colonoscopy, polypectomy, haemostatic
therapy, balloon dilation, and placement of percutaneous endoscopic gastrostomy (PEG)
tube. These are fundamental to the assessment, treatment, and care of infants and
children with various gastrointestinal disorders.9
It is essential that safety is maintained through acquisition of adequate medical
knowledge and technological know-how specific to performing gastrointestinal
endoscopic procedures in children,10 in order to ensure effectiveness.
Medical gastrointestinal endoscopy in paediatric population ranging from neonates to
adolescents is usually undertaken in most reference centres by certified paediatric
gastroenterologists trained in accredited fellowship programmes,2,9,10 who ensure that
standard protocols are maintained including pre-procedure preparation of patients, peri-
procedure maintenance as well as continued post-operative care.
Preparation for endoscopy in paediatric patients requires the physician paying attention
to the child’s physiology as well as  the emotional and psychosocial wellbeing of both
patient and his/her primary caregivers.9 Early emotional, psychosocial support of the
child and the parents/caregivers are beneficial in endoscopic procedures particularly in
2centres where conscious sedation is used.11 The parents/legal guardian of the child
should be adequately counselled about the procedure and the child if s/he is old enough
otherwise relevant role play models could be applied in counselling the younger child.
However, in most tertiary centres with adequate anaesthetic support, general anaesthesia
is preferred in children as it is associated with improved outcomes. Also in children less
than three years, the airways have to be protected from the compression exerted by
gastroscope as it is being passed, hence the preference for general anaesthesia.
Informed consent should be obtained from an appropriately designated parent or legal
guardian as required by the State while assent should be obtained when appropriate from
an older child.9 When obtaining consent, the nature of the procedure including risks of
anaesthesia and its possible complications should be explained.
These complications could be related to sedation/anaesthesia, procedure or patient’s
underlying condition and include hypoxia, bleeding, respiratory distress,
nausea/vomiting, gut perforation, pneumoperitoneum among others.  However the risks
are very rare and by and large the therapeutic and diagnostic benefits of endoscopy by
far outweigh these risks.11,12,13,14 In a cross- sectional database review of  the
complications arising from OGD from 13 facilities between 1999-2003 that reviewed
10,236 procedures performed in 9234 paediatric patients, reported an immediate
complication rate of 2.3% associated with OGD. The most common complications noted
in that study were hypoxia (1.5%) and bleeding (0.3%). A higher complication rate was
seen in the youngest children who desaturates easily, those with highest American
Society of Anaesthesiologists class (ASA), or received intravenous sedation rather than
general anaesthesia. 12
Absolute contraindication should be identified prior to the procedure and include
unstable airway, cardiovascular collapse, intestinal perforation and peritonitis, while
relative contra-indication are bowel obstruction, severe thrombocytopaenia,
coagulopathy, recent gastrointestinal surgery, respiratory infection and recent food
intake prior to the commencement of the procedure as patient must be fasted as per
protocol.3,15,16
Further as part of the pre- colonoscopy preparations adequate bowel cleansing of the
patient with standard bowel preparation regimens prior to the procedure is essential for
3clear endoscopic field.17 Various cleansing regimens including polyethylene glycol with
electrolytes, polyethylene with normal saline enema, bisacodyl suppositories are in use
either singly or in combination.18 However, no standardized bowel preparation regimen
or paediatric colon cleanliness index exists for children; recommendations have been
made concerning pre-procedural preparation complemented by the individual experience
of the specific endoscopic centres.3 This bowel preparation should be emphasized so as
to allow for a clear visible gut during the colonoscopy.
Some gastrointestinal endoscopic procedures require pre-procedural parenteral antibiotic
prophylaxis such as during PEG tube insertion because of its high risk of infection.
Antibiotic recommendation therefore has to be determined by a combination of
procedure-related risk of bacteraemia and patients’ risk,12 and as well as local
experience.
Patient’s monitoring during endoscopic procedures is crucial for a successful procedural
outcome.  The American Academy of Paediatrics has issued recommendations regarding
sedation and monitoring for diagnostic and therapeutic procedures in children.19 These
guidelines recommend continuous pulse oximetry, and heart rate monitoring at all levels
of sedation by a dedicated trained attendant who is specifically assigned to monitor the
child’s vital signs including oxygen saturation, heart rate, respiratory rate, blood
pressure and in some settings electrocardiography. Monitoring of vital signs during an
endoscopic procedure is important particularly in younger children as they can
desaturate easily without showing obvious signs and symptoms.3
Gastrointestinal endoscopy has stood out as an accurate and informative method of
assessing upper and lower gastrointestinal disorders and the procedures should therefore
be performed only in clinical conditions in which it has shown superiority over other
diagnostic methods,9 to improve its diagnostic yield and therapeutic impact on the
management of patients.
Various leading societal expert groups including North American Society for Paediatric
Gastroenterology Hepatology and Nutrition (NASPGHAN) and European Society for
Paediatric gastroenterology Hepatology and Nutrition (ESPGHAN) have assessed the
different guidelines for the use of gastrointestinal endoscopy in children.20 The objective
4is to have a clear underlying evidence that findings from the endoscopic procedure will
impact positively on patient’s diagnosis and/or treatment.
Endoscopy is not usually indicated in older children for the evaluation of functional
gastrointestinal disorders, including self- limited abdominal pain, constipation and
incontinence.21Exceptional indications may include children with ‘red flag’ symptoms
and signs such as abdominal pain waking the child up from sleep, other associated
systemic symptoms like fever, joint pain or unusual rash, significant vomiting especially
with bile or blood, recurrent mouth ulcers, associated malnutrition or poor growth;
dysphagia; and mucous or blood in the faeces.6
Gastrointestinal symptoms including haematemesis, chronic abdominal pain, persistent
vomiting, anaemia, dysphagia, and foreign body ingestion are indications for endoscopy.
OGD is particularly useful in evaluating common paediatric foregut disorders including
allergic, infectious, peptic oesophagitis and gastritis, coeliac disease, as well as diagnosis
and treatment of strictures and variceal bleeding in children with portal hypertension
arising from different aetiologies.6,22
Colonoscopy may be performed in infants and children with rectal bleeding. A diagnosis
of inflammatory bowel disease can be established as well as defining the extent and the
severity of the disease, which may identify complications and influence initial
management. It can also be important in follow up assessment of disease progress.
Further uses of colonoscopy may also include diagnosing causes of allergic colitis,
colitis caused by other conditions like granulomatous diseases including mycobacterium
organisms as well as lower gastrointestinal haemorrhage, chronic diarrhoea, cancer
surveillance/follow up particularly in children with multiple polyposis syndrome.
Therapeutic colonoscopy is used in the management of polyps, foreign body removal,
stricture dilatation, percutaneous caecostomy as well as reduction of intussusception.23,24
With further technological advancements newer modalities of endoscopy have been
developed including small bowel enteroscopy and wireless capsule endoscopy. Wireless
capsules passed via the oral route  allow mucosal visualization of the small bowel (from
the duodenum to the caecum) thus aiding the diagnosis of some gastrointestinal
pathologies previously posing with diagnostic dilemmas including occult gastrointestinal
5bleeding, suspected Crohn’s disease, Coeliac disease, and small bowel polyps in
individuals with hereditary polyposis syndromes.3,25
The sensitivity/diagnostic yield of all endoscopic examinations in paediatric patients
varies with the age of the child and indication for the procedure. In upper
gastrointestinal endoscopy, Chang and colleague, 26 reported an 85% ability of the OGD
to pick up source of upper gastrointestinal bleeding in a cohort of 23 patients.  In another
study of 16 patients undergoing upper gastrointestinal endoscopy six out of the 16
patients (37.5%), had endoscopically detected abnormalities despite normal radiographic
reports.27
The results of biopsy in endoscopic procedures have markedly improved the diagnosis
of some gastrointestinal diseases including Helicobacter pylori infection related gastritis
and small intestinal ulcers, Coeliac disease, inflammatory bowel disease (IBD) and
associated secondary infections  during acute flare up of  ulcerative colitis including
Cytomegalovirus colitis/infection.28
Tissues biopsies taken during colonoscopy from abnormal  and even macroscopically
normal parts of the gut have helped to diagnose some common differentials of colitis in
children particularly abdominal tuberculosis in our setting, enabling treatment with anti-
tuberculous therapy in such cases with often good prognosis thus sparing such children
the risks of being labelled as possible cases of IBD particularly Crohn’s disease and its
treatment with various immunosuppressive agents and the attendant side effects as well
as indirect economic costs to the child and affected families.29
During upper gastrointestinal endoscopy biopsies should be obtained from different sites
for histological diagnosis; as even in the absence of any macroscopic findings on
endoscopy, important diagnoses have been made from tissue biopsies obtained from
normal appearing parts of the gut, thus enabling either a modification or change of
patient’s management for the better in such circumstances. In a study by Thakkar and
colleagues30 the overall rate of change of management after endoscopic evaluation in
children with IBD was 42% necessitating addition of a new medication as the most
common intervention.
6In parallel to the growth of paediatric gastroenterology sub-speciality,
gastroenterological disorders requiring endoscopy for diagnosis, therapy and
surveillance/follow -up have shown a rising incidence globally. With the development of
fibre-optic endoscope, gastrointestinal endoscopy has become a revolutionary diagnostic
as well as therapeutic tool.  Endoscopy has shown superiority in terms of diagnostic
yield over earlier methods of diagnosing common as well as rare gastrointestinal
disorders.31
A gap in knowledge exists on gastrointestinal endoscopy practice in children in the sub-
Saharan Africa with limited data reported mostly by adult gastroenterologists in Zambia,
Sudan, and Nigeria.32, 33,34 There has been a rapid increase in the need for upper and
lower gastrointestinal  endoscopy in children in our setting where key health focus is
skewed towards prevention and control of endemic infectious diseases.
Hence, the objectives of the study were to determine the  socio-demographic
characteristics; presenting symptoms; indications; diagnostic yields; impact on
management; complications and to design algorithms for medical indications of
gastrointestinal endoscopy in children.
1.2 Ethical Consideration
All study data collection tools used to collect relevant subjects information from medical
records, Division of Gastroenterology and Histopathological Laboratory databases were
stored in a well secured locker. Retrieved subjects’ data were subsequently transferred to
electronic data and stored in a pass worded secured database.
All data set used for the study analysis were void of any patient’s identifying
information and the participant’s folder identified by the assigned  study number to
maintain anonymity.
The list containing subject’s names and study numbers were stored separately from the
data collection tools. The data set was subsequently reviewed and cleaned up to ensure
absence of coding errors prior to the statistical analysis.
Potential risks: This was a retrospective review of medical records with anonymity.
There were no direct contact with subjects and hence no human risks or harms were
anticipated in the current study and individual informed consent was waived.
7Potential benefits: Results from this study will help to improve medical gastrointestinal
endoscopy service in children in our setting. Feedback from the study results will guide
appropriate selection of children needing gastrointestinal endoscopy with improvement
of impact of endoscopy in management of children with various gastrointestinal
disorders.
Data from this study will be presented at 52nd Annual General Meeting  of ESPGHAN
in Scotland in 2019 and will be submitted for publication in an international journal with
Thomson Reuters impact factor.
Ethical approval: Study ethical approval was obtained from the University of Cape
Town, Faculty of Health Science Human Research Ethics Committee (HREC REF:
089/2017) and written permission from the Red Cross War Memorial Children’s
Hospital Research Committee and Management prior to the commencement of the
study.
1.3 Chosen journal for publication
The Journal of Pediatric Gastroenterology and Nutrition (JPGN) was chosen for possible
publication of this research. JPGN is the official journal of the European Society of
Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and the North
American Society of Pediatric Gastroenterology Hepatology and Nutrition
(NISPGHAN). Both societies are the leading organizations in the field globally with
eminent scholars in the field publishing best practice guidelines. JPGN is a peer
reviewed medical journal with wide scope covering medical research in paediatric
gastroenterology, hepatology and nutrition.
The current study to the knowledge of the researchers is the first comprehensive review
of medical gastrointestinal endoscopy in children in the sub- Saharan African region
undertaken by paediatric gastroenterologists and their trainees and will serve as a base
for future research on the subject not only in our setting but also globally.
This paper has been formatted according to the author’s guidelines of the Journal of
Paediatric Gastroenterology Hepatology and Nutrition (See attached appendices).
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ABSTRACT
Background: Endoscopy is an important diagnostic, therapeutic and surveillance modes
of management in children with gastrointestinal disorders.
The objectives of the  study were to determine the  sociodemographic characteristics,
presenting symptoms, indications; diagnostic yields, management impact,
safety/complications and design algorithms for the medical indications of
gastrointestinal endoscopy in children.
Methods: This was a cross sectional descriptive study in children <18years  who
underwent gastrointestinal endoscopy (2007 – 2016).
Ethical approval was obtained from University of Cape Town.
Datasheet was used in retrieving relevant patients’ variables from the hospital medical
records  and Division of Paediatric Gastroenterology endoscopy  and laboratory
databases. Data was analysed using Stata 13.1. A p- value of less than 0.05 was
considered statistically significant.
Results:
A total  of 402 children underwent 773 endoscopies: 670 were
oesophagogastroduodenoscopy (OGD), 103 colonoscopies with 78(10.1%)  being
combined OGD/colonoscopy procedures.
Main diagnostic indications for OGD, combined  OGD/colonoscopy and colonoscopy
alone respectively were chronic abdominal pain 51 (12.6%), probable inflammatory
bowel disease (IBD) 30(7.5%) and IBD 30(7.5%).
Change  143(35.6%)/insertion 87(21.6%) of percutaneous endoscopic gastrostomy and
polypectomy 8 (2.7%) were the most common therapeutic indications for OGD and
colonoscopy respectively.
The overall diagnostic yield was 64.8% (116/179) for OGD and 62.7% (42/67) for
colonoscopy respectively. Significant endoscopic impact  298(74.1%) on patients
management was observed (p<0.001) while complications occurred in 4.0% (16).
Conclusion:
Significant endoscopy yields and impact on patient’s management with low
complication rate were observed.
Use of standard guidelines to ensure selection of patients with appropriate indications
for endoscopy should be encouraged for significant impact on management.
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What is known? Technological advancements in endoscopy
design and its devices have led to the
evolution of paediatric gastrointestinal
endoscopy with increasing use in
diagnostic, therapeutic and surveillance
modes of management.
What  is new? -Gastrointestinal endoscopy procedures
may not add to patients management if
clear indications are not present and the
procedures should therefore be performed
only in clinical conditions in which it has
shown superiority over other diagnostic
methods.
-Appropriate selection of cases with clear
indications will result in high diagnostic
yields that will impact on patient’s
management.
-Eosinophilic oesophagitis (EoE), Coeliac
disease and inflammatory bowel diseases
are not common in our setting.
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INTRODUCTION
Paediatric endoscopy has evolved to become an important diagnostic, therapeutic and
surveillance modes of management in children with various gastrointestinal disorders1,2
owing to the technological advancements in endoscopy design and its devices.3,4
Improvements in sedation, anaesthesia4 and skills in monitoring of vital signs of
patients,5 during endoscopic procedures have  added to the increased and safe use of
gastrointestinal endoscopy in children and neonates.5,6,7
Indications for gastrointestinal endoscopy are diverse and fundamental to the
assessment, treatment, and follow- up/surveillance of children with gastrointestinal
disorders8 with high diagnostic and therapeutic yields and should be performed in
clinical conditions in which it has shown superiority over other diagnostic modalities.8
Biopsy results from endoscopies have improved the diagnosis of some gastrointestinal
diseases as diagnoses could be made from histopathological examinations of tissue
biopsies obtained from both macroscopically normal and abnormal looking tissues on
endoscopy. 9
The sensitivity of endoscopic examinations varies with the age of the child and
indication for the oesophagogastroduodenoscopy (OGD) and colonoscopy procedures
respectively. 10,11
Several published societal guidelines exist for the performance of gastrointestinal
endoscopy in children12,13,14 which recommended that there should be its clear
indications such that  the findings could impact on  management.
There is paucity of data on paediatric gastrointestinal endoscopy in sub- Saharan
African region with most studies jointly reported with adult gastroenterologists.15,16,17
The objectives of the study were to assess the  sociodemographic characteristics,
presenting symptoms, indications, endoscopic yields, management impact,
complications and design algorithms for the medical indications of gastrointestinal
endoscopy in children.
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PATIENTS AND METHODS
Study setting:
This study was conducted at Red Cross War Memorial Children’s Hospital (RCWMCH)
which is a tertiary paediatric hospital affiliated to the University of Cape Town, in Cape
Town, South Africa.
All gastrointestinal endoscopies in children in  the hospital were done following
standard protocols and under general anaesthesia by either consultant paediatric
gastroenterologists, a paediatric surgeon or trainee paediatric gastroenterology fellows
under supervision.
Routine diagnostic, therapeutic and surveillance endoscopies are done in the unit. For all
diagnostic gastrointestinal endoscopies done, multiple mucosal biopsies were taken from
different parts of the gastrointestinal tract as follows: upper gastrointestinal tract –
oesophagus (upper, mid and lower), stomach (body and antrum), and duodenum (first
and second parts); lower gastrointestinal tract (rectum, sigmoid, descending, transverse,
ascending colon, caecum, and terminal ileum). Biopsies were procured from both
normal and abnormal appearing  mucosa of the gastrointestinal organs for diagnosis.
Histological diagnosis of mucosal disease was made by a well experienced pathologist.
Study design
It was a retrospective cross sectional descriptive  study undertaken among children and
adolescents who underwent gastrointestinal endoscopy in RCWMCH from 1st January,
2007 to 31st December, 2016.
Study population
This comprised all children and adolescents who underwent upper and lower
gastrointestinal endoscopy in the Paediatric Gastroenterology Division during the period
under review.
Sample Size determination:
Out of 415 subjects identified from the medical records 13 were excluded as 11 had
missing folders while 2 had incomplete records leaving 402(96.9%) children  with
complete records to be studied.
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Inclusion criteria
All children who had medical gastrointestinal (oesophagogastroduodenoscopy and/or
colonoscopy) endoscopy from 1st January, 2007 to 31st December, 2016  with complete
medical records were studied.
Exclusion criteria:
Subjects with missing folders, incomplete folders and/ or medical records documented.
Permission for the Study:
Study ethical approval was obtained from the University of Cape Town (UCT), Faculty
of Health Science Human Research Ethics Committee (HREC REF: 089/2017) while
written permission was obtained from the RCWMCH Research Committee and
Management prior to the commencement of the study (See Appendices).
Study Datasheet:
Data was collected using datasheet designed for the study from the medical records of
subjects identified by Clinicom (a clinical software for entering diagnosis in the
republic of South Africa health System) search using the current ICD10 codes  (1552;
1553;1587; 1588;1653;1589;1591; 1653;1597) for medical gastrointestinal endoscopic
procedures. Data sheets were used in retrieving other relevant variables of  patients from
the Division of Paediatric Gastroenterology endoscopy  and laboratory (histopathology)
databases respectively during the period under review.
Relevant  information were retrieved from the medical records of each patient  including
sociodemographic characteristics, initial presenting symptoms, type of gastrointestinal
endoscopy performed  (OGD, OGD with colonoscopy or  colonoscopy alone) with
specific indication/s, macroscopic findings on endoscopy, complication/s following
endoscopy, histological diagnosis, and any change in management post endoscopic
procedure were obtained.
Diagnostic yield of endoscopy  in the current study  were classified as either positive
(presence of any  macroscopic endoscopic or histologic abnormality found excluding
mild inflammation  on histology) or negative (no or minor abnormality/normal his
tology) effecting a positive contribution.18, 19
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The endoscopic procedures were further subdivided into 2 categories: a positive
contributive impact (the procedure had a positive impact on diagnostic and/or
therapeutic modalities) and non- contributive impact (a procedure with no diagnostic or
therapeutic effect).
In our centre, RCWMCH, cases  of foreign body and caustic ingestions as well as
laparoscopic insertion of percutaneous gastrostomy tube are undertaken by the
paediatric surgical team on separate endoscopy lists while the paediatric
gastroenterology unit undertakes the medical endoscopy cases mainly for diagnostic
OGD and colonoscopy as well as therapeutic indications of gastrointestinal
endoscopy(insertion/change of percutaneous gastrostomy tube, banding or sclerotherapy
for oesophageal/gastric varices, polypectomy) among others
Socioeconomic class determination:
Patients were classified as low, middle, or high socioeconomic class according to their
gross income  per annum for the purposes of service fee determination.
Low income: H0- social  grants(fully subsidized) or H1: (<70, 000R (4800USD)/annum
for individual or single or less than R100,000(6900USD) for household/family unit),
middle income, H2- (equal to or more than R70, 000 (4800USD) but < R250, 000
(17,300USD)/annum for individual/single or equal to  or more than R100,000
(4800USD)  but less than R 350,000 (24,200USD) for household/family unit), and high
income, H3 (equal to or >R250, 000 (17,300USD)/annum for individual/single,  or
equal to or  more than R350, 000 (24,200USD)/annum  household/family unit)
respectively.20
The socioeconomic distribution of patients studied  was adapted using the uniform fee
schedule regulations for health care services rendered by the Western Cape Department
of Health South Africa, 2017, 18 as the study was conducted at Red Cross War Memorial
Children’s Hospital, Cape Town, which is a public hospital in the Western Cape
Province.20
Data Analysis:
Data was captured in Microsoft Excel spread and exported to  Stata 13.1 for statistical
analysis. Categorical variables were presented as frequency tables, and numerical
variables as descriptive measures, expressed as median and range.
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The association between categorical  variables was assessed using Pearson chi- square
test and student t- test where appropriate.
Endoscopy diagnostic yield was calculated  for  initial examination involving  diagnostic
indications for upper and lower endoscopy respectively and change in and contribution
to management was assessed.
Algorithms of the indications for upper and lower endoscopy in children were
subsequently designed using the results obtained from the study.   A p- value of less than
0.05 was considered statistically significant.
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Results
Study subjects characteristics:
Four hundred and two patients were studied. Females were 220(54.7%)  with a male  to
female ratio of 0.8: 1. Their median age was 5.5 (range: 0.1 – 18) years  with majority
394 (98.0%) being  younger than 13years old and of normal weight 276 (68.6%) while
most were of low socioeconomic class, 307(76.4%) (Table 1).
Endoscopic procedures:
A total of  773 gastrointestinal endoscopies were undertaken. Total OGD done was 670
(86.7%) out of which 592(76.6%) and 78(10.1%) respectively were OGD alone and
OGD combined with colonoscopy. One hundred and three colonoscopies with 78
(10.1%)  being combined OGD/colonoscopy and  colonoscopy alone 25(3.2%) were
also performed  (Table 1).  The median OGD and colonoscopy performed  per patient
was 1 (range 1 to 12)   and (1 to 4) respectively.
Presenting symptoms among subjects:
The presenting symptoms for OGD, combined OGD/colonoscopy and colonoscopy
alone were as shown in Figure 1a, 1b, and 1c respectively. Feeding difficulty/poor
feeding 102 (25.4%), poor weight gain/failure to thrive/loss of weight 100 (24.9%),
upper gastrointestinal bleeding 81 (20.1%), and recurrent aspiration/silent aspiration
76(18.9%) were the most common presenting symptoms in children undergoing OGD.
Among patients that had combined OGD with colonoscopy the most common presenting
symptoms were chronic abdominal pain 27 (6.7%), chronic bloody loose stools 16
(4.0%), and chronic diarrhoea 15(3.7%).
Also in patients who underwent only colonoscopy the most common presenting
symptoms were rectal bleeding 11(2.7%) and chronic bloody loose stools 7(1.7%).
Indications for endoscopy:
Among 670 OGD  performed 179 (26.7%), 287(42.8%), 204 (30.4%) were respectively
for diagnostic, therapeutic and follow – up/surveillances indications.
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Among 103 colonoscopy undertaken 67 (65.0%), 30 (29.1%), 6 (5.8%) were for
diagnostic, follow-up/surveillance, and therapeutic indications respectively.
The main diagnostic indications for OGD were: chronic abdominal pain, 51(12.6%),
gastro-oesophageal reflux 30 (7.5%),  probable eosinophilic oesophagitis (EoE) 17
(4.2%),  chronic diarrhoea 17 (4.2%),  coeliac disease 9(2.2%), food allergy 6 (1.5%),
aspiration 5 (1.2%) among others while the therapeutic indications  for OGD included:
insertion of percutaneous gastroscopy (PEG) tube 87 (21.6%), change of PEG  143
(35.6%); sclerotherapy 29 (7.2%) and variceal band ligation 28 (7.0%) for various
causes of upper gastrointestinal bleeding/portal hypertension.
The follow – up/surveillance indications for OGD were mainly for previous upper
gastrointestinal bleeding secondary to oesophageal varices 204(50.7%).
The major diagnostic indications for combined OGD and colonoscopy were
inflammatory  bowel disease, IBD 30 (7.5%), chronic diarrhoea 12 (3.0%), abdominal
tuberculosis 10 (2.5%), chronic abdominal pain 10 (2.5%), chronic iron deficiency
anaemia 6 (1.5%), IBD screening in those with autoimmune hepatitis 3 ( 0.7%), protein
losing enteropathy 2 (0.5%) while follow up/surveillance indications were mainly for
inflammatory bowel disease  2 (0.5%).
Diagnostic indications of colonoscopy were IBD 30 (7.5%), lower gastrointestinal
bleeding 26(6.5%),  abdominal tuberculosis 9 (2.2%), bloody diarrhoea 2(0.5%) while
the therapeutic colonoscopy indications were for polypectomy 6 (100.0). Also 30 (7.5%)
cases were for IBD follow -up/surveillance (Table 2).
Terminal ileum intubation and caecal examination rate:
Among 103 colonoscopies done, successful terminal ileum   intubation and caecal
examination rate was achieved in 95 (92.2%) cases.  Five (4.9%) cases were procto-
sigmoidoscopies for follow up of IBD while 3(2.9%) had failed terminal ileum
intubation (Table 1).
Diagnostic yields:
Abnormal (positive) macroscopic findings on endoscopy were reported on
79/179(44.1%), 35/68(51.55%), and 46/67(53.7%) of OGD, combined OGD with lower
endoscopy, and colonoscopy alone respectively.
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Upper gastrointestinal bleeding showed the highest percentage 72.1%(31/43) on
abnormal endoscopic (OGD) findings.
Also,  positive histological findings on OGD, combined OGD with colonoscopy, and
colonoscopy alone were 62/179(34.6%), 34/68(50.0%), and 32/67(47.8%) respectively.
See Table 3.
The overall normal endoscopic findings (both macroscopic findings on endoscopy  and
histological findings) were 63/179(35.3%) and 25/67(37.3%) for OGD and colonoscopy
(see Table 3) while overall diagnostic (endoscopic) yield was 116/179(64.8%) for OGD
and 42/67(62.7%) for colonoscopy respectively which were significantly high.
As depicted in figure 2, the OGD endoscopic yield reported gastritis in 50(27.9%),  and
oesophageal varices 31(17.3%) while inflammatory bowel disease (Crohn’s disease
9(13.4%), ulcerative colitis 7(10.4%), juvenile polyps 9(13.4%) and intestinal
tuberculosis 7(10.4%) were observed on colonoscopy respectively.
On test of association between the macroscopic endoscopic findings to histological
findings, significant statistical association was observed in some OGD diagnostic
variables including chronic abdominal pain (p = 0.026) and upper gastrointestinal
bleeding (p= <0.001). Other variables in both OGD and lower scope did  not show any
significant statistical relationship (p>0.05). See Table 3 (Supplementary Digital
Content)
The relationship between the different sociodemographic characteristics and OGD
diagnostic yields were not statistically significant: age (p = 0.197), sex (p= 0.403),  and
socioeconomic class (p= 0.400). Similarly no significant statistical relationship was
observed between the different sociodemographic characteristics and colonoscopy
diagnostic yield: age (p = 0.774), sex (p= 0.248), and socioeconomic class (p= 0.440)
respectively.
Percutaneous endoscopic gastrostomy insertion/change:
A total of  230 PEG procedures were undertaken comprising 143(62.2%) change of PEG
to gastrostomy tubes and 87 (37.8%) PEG insertions. The indications for PEG insertion
included feeding in children  with neurological deficits particularly cerebral palsy,
traumatic brain injury, prolonged unconsciousness with unsafe swallowing, silent
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aspiration or FTT/poor weight gain, difficulty/inco-ordinate swallowing and for
medication adherence in patients with acquired immune deficiency syndrome.
Among patients who underwent endoscopy for PEG insertion, there was significant
increase in weight upon their feeding via gastrostomy tubes among affected patients.
From the study  the  median weight for age z-scores pre- PEG insertion  among affected
patients was -2 (range: -3 to  +1)  which increased to  0 ( -1  to +2) at the time of change
of PEG to gastrostomy tubes (and the difference was statistically significant (p < 0 .001).
The PEG were changed to a gastrostomy tube after a mean period of 3.7(range 3.0- 12.0)
months  with  2 (1.4%) patients changed to a Mickey type of gastrostomy tube.
Impact of gastrointestinal endoscopy on management:
All the endoscopies including OGD, OGD/colonoscopy and colonoscopy alone
(diagnostic/therapeutic/surveillance) done showed a positive impact on the management
of 298 (74.1%) patients (p < 0.001).
The impact  of endoscopy on the management reported included feeding via inserted
PEG tube 141 (47.3%),  addition of new medication/s 70 (23.5%), treatment of varices
using either sclerotherapy 29 (9.7%) or band ligation 28 (9.4), polypectomy 8 (2.7),
therapy for eradication of Helicobacter pylori associated gastritis 8 (2.7%), change of
medication/s for different gastrointestinal conditions 6 (2.0), nutritional therapy using
exclusive enteral nutrition for Crohn’s disease/minimal fat diet 5 (1.7%), or PEG
insertion for medications adherence for  patients on  highly active anti- retroviral therapy
2(0.7%).
There was no change in treatment in 104(25.9%) of patients.
Safety/Complications:
The majority 386(96.0%) of cases had no complications/safety concerns following
endoscopy. Complications occurred in 16 (4.0%) patients. The  major complications
were anaesthetic related or following PEG insertion: bradycardia/hypotension 2 (0.5%),
failed extubation 1 (0.2%), de- saturation 1 (0.2%), pneumo- peritoneum 1 (0.2%),
stridulous breathing on extubation 1(0.2%), or  retained/ buried bumper following  PEG
insertion (n= 1 (0.2%)) while minor complications included: pulling out/falling- off of
gastrostomy  tube 7(1.7%), PEG skin site infections 1(0.2%), over- granulation tissue
formation following PEG insertion 1 (0.2%). No  mortalities were observed among the
patients.
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The algorithms for the  various indications for performing OGD, combined OGD with
colonoscopy and colonoscopy alone among patients  were designed  using the observed
results  (Supplemental Digital Contents -Tables 2 to 5).
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Discussion
Paediatric gastrointestinal endoscopy has advanced  in the last few decades allowing a
greater understanding of various gastrointestinal disorders,  and becoming an invaluable
modality in diagnosis, therapy, follow-up/surveillance of most gastrointestinal
diseases.2,13 The current study is the first most comprehensive report of paediatric
gastrointestinal endoscopy undertaken by paediatric gastroenterologists and trainees in
the sub-Saharan African region. 21,22,23
The median age of the patients in the present study was 5.5 (range: 1 month to 18) years
which is comparable to  findings in similar studies.23, 24 Most of the patients in the
current study were young with only 2.0%(8) of them being older than 13years. This is a
paediatric study bias as the hospital  does not accommodate patients over 13years.
Various sociodemographic characteristics including age, sex, socioeconomic class did
not significantly influence the positivity of diagnostic yields both for OGD and
colonoscopy, unlike in a similar study18 where age was a determinant factor. From the
study most of the patients were  females and  of low socioeconomic background. However
social  class and gender distribution of patients did not significantly influence the endoscopic
yield.
Studies have shown  significant association between incidence and outcome of common
gastrointestinal conditions  including coeliac disease  and assessing endoscopy services with
socioeconomic class of patients as cost implications could be a limiting factor in
management.25,26
In our setting majority of the patients enjoyed government subsidized medical care either
wholly or  in part and so most of the patients  though of low socioeconomic class had equal
access to standard medical care, 20 including gastrointestinal endoscopy.
However,  Akbulut and co- workers27 as well as Vazou et al 28 corroborated  the finding in the
current study that gender has no effect on the diagnostic yield in children with chronic
abdominal pain  and type 1 diabetes undergoing upper endoscopy.
Abdominal pain has been reported as the most common indication for OGD in most
similar studies.16, 19 This  was corroborated in the diagnostic indications of OGD in the
present study.
In addition  feeding difficulty/poor feeding with poor weight gain/failure to thrive (FTT)
were the most prevalent indications for performing therapeutic OGD in the current
study. In our centre therapeutic upper endoscopy mainly for insertion/change of PEG for
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feeding, or for medications   to maintain drug adherence in children with AIDS and
having inco-ordinate swallowing were routinely carried out.
Rectal bleeding and chronic bloody loose stools were the two leading indications for
colonoscopy in the present study which is similar to findings by other workers.29, 30
Chronic abdominal pain was the most common diagnostic indication while insertion/or
change of PEG and sclerotherapy/or  band ligation for oesophageal varices were the two
leading indications for therapeutic OGD. This experience in the current study
corroborates the recommendations by key expert societal guidelines on indications for
performing endoscopy in paediatric age range.13
Combined OGD and colonoscopy have been recommended for the diagnoses and
follow-up of some paediatric gastrointestinal disorders including IBD, polyposis, and
chronic diarrhoea 31, 32 as in the current study.
Most paediatric gastrointestinal disorders present with different symptoms and signs and
often definitive  diagnoses are not  made explicit as  combined presenting symptoms and
signs are used for various presumptive clinical diagnoses as in the present study. 8, 13, 31
Identification of caecal landmarks including the opening of the appendix during
colonoscopy has been shown as the gold standard for its completeness. It is invaluable in
the diagnosis of some gastrointestinal disorders including IBD, intestinal  tuberculosis,
chronic diarrhoea among others. 33, 34 Terminal ileum intubation rate of 92.2% was
observed  in the current study which is  higher  than findings in similar studies 33, 34 The
high caecal examination and terminal ileum  intubation rate in the present study could
be as a result of adequate bowel preparation, use of general anesthesia and experience of
the paediatric gastroenterologists allowing higher colonoscopy endoscopic yield and
therapy.
The overall endoscopic yield for upper and lower endoscopy in the present study was
significantly high. High diagnostic yields have equally been reported for OGD and
colonoscopy in similar studies18,19, 35,36 The high endoscopic yield observed in the
present study could be due to appropriate selection of cases for endoscopy using
standard  societal guidelines,37 pre- procedure preparations including bowel
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preparations as well as obtaining of biopsies at the time of endoscopy from both
macroscopically normal and abnormal looking gastrointestinal mucosa.38 The usefulness
of obtaining biopsies from normal looking mucosa is known to improve diagnostic
yields in paediatric gastrointestinal endoscopy.39 Also negative histopathological
findings on biopsies may be useful in excluding diagnoses thereby relieving anxiety
amongst patients and families 40 as well as averting need for further investigations.
However, considering the potential complications and costs of gastrointestinal
endoscopy under general anaesthesia, appropriate clinical judgment should be applied in
selecting patients with the right indications.41Some  macroscopic findings on endoscopy
showed  significant statistical relationship with histopathological diagnosis in the present
study as previously reported.2
There was a significant impact of gastrointestinal endoscopy in the current study. These
impacts included both diagnostic and therapeutic modalities. In the present study,
colonoscopy biopsies of terminal ileal pathology were important in distinguishing
intestinal tuberculosis  from Crohn’s disease. Both Crohn’s disease and intestinal
tuberculosis may have similar presentations so that it is important to exclude
tuberculosis before starting immunosuppressive treatment for IBD42 as was seen in the
current study.
Most children with feeding difficulty/poor weight gain mainly with neurological
disorders like cerebral palsy had  OGD  for insertion of PEG  for adequate  feeding  thus
ensuring that their daily recommended dietary allowances  are met resulting in improved
growth as evidenced by their appreciable increase in median weight for age Z- scores.
Similar findings have been corroborated by other workers.43, 44, 45 Also children with
poor medications adherence particularly those with HIV/AIDS having swallowing
difficulties in the present study had PEG insertion, allowing regular administration of
their medications thus averting development of  drug resistance.43
Other therapeutic modalities of gastrointestinal endoscopy in the present study that
impacted positively on the outcome included: sclerotherapy or band ligation for bleeding
oesophageal varices or eradication of oesophageal varices in patients with biliary atresia
with associated portal hypertension or  extra- hepatic portal vein thrombosis and those
with juvenile polyposis that had polypectomies. Similar reports have been documented
by other researchers.45, 46 Also Thakker et al9 had reported a 42%  change in
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management mainly addition of new medication/s  after repeat endoscopy in children
with IBD thus improving their treatment outcomes similar to the current study.
No mortalities were reported in the current study similar to other studies.47 Most of the
complications in the current study were anaesthetic related and following PEG insertion
as have been reported by other researchers. 45, 48, 49, 50
Conclusion:
OGD and lower endoscopy were performed for different diagnostic, therapeutic and
surveillance indications among study subjects with different presenting symptoms. A
high degree of endoscopic yield of both OGD and colonoscopy were observed with
significant diagnostic and therapeutic impacts on patients’ management with minimal
safety concerns/complications which were mainly  general anaesthesia  related.
Recommendation:
Use of expert societal guidelines in selecting  patients with appropriate indications for
gastrointestinal endoscopy will result in higher endoscopy diagnostic yields and
therapeutic applications of endoscopy, positive  impacts  on patients’ management with
minimal complications.
Conflicts of interest: The  authors hereby declare that we have no  conflicts of interest
in the manuscript, including financial, consultant, institutional and other relationships
that might lead to bias.
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Table 1 :   Socio- demographic and endoscopic characteristics of study subjects
Characteristic n = 402(%)
Age (years):
Median 5.5
Range 0.1 – 18.0
Sex:
Male 182 (45.3)
Female 220 (54.7)
Socio economic class:
Low 307 (76.4)
Middle 57(14.2)
High 38 (9.5)
Weight  for age z- score:
-1 < WAZ < 0 (normal)                                                                         276(68.6)
-2 < WAZ <-1 (marginal underweight) 23(5.7)
-3 < WAZ < -2 (moderately underweight)                                            42 (10.4)
WAZ < -3  (severely underweight)                                                       61(15.2)
Endoscopy Performed:
Overall oesophagogastroduodenoscopy + Colonoscopy
performed                                                                                           773(100.0)
Total oesophagogastroduodenoscopy                                                    670 (86.7)
Oesophagogastroduodenoscopy  alone                                                  592(76.6)
Total Colonoscopy 103 (13.3)
Colonoscopy alone 25(3.2)
oesophagogastroduodenoscopy + Colonoscopy
(combined procedures) 78 (10.1)
Indications for Endoscopy:
oesophagogastroduodenoscopy (total) 670 (100.0)
Diagnostic 179 (26.7)
Therapeutic 287 (42.8)
Surveillance 204 (30.4)
Colonoscopy(total): 103 (100.0)
Diagnostic 67 (65.0)
Follow- up/Surveillance 30 (29.1)
Therapeutic 6 (5.8)
Percutaneous endoscopic gastrostomy( PEG); n= 230:
Change  of PEG 143(62.2)
Insertion of PEG 87(37.8)
Terminal ileum/Caecal intubation:
(for colonoscopy, n= 103):
Yes 95 (92.2)
No 8  (7.8)
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Table 2:   Indications for gastrointestinal endoscopy among study subjects
Characteristic N=402(%)
A. Oesophagogastroduodenoscopy only (N=670)
(i) Diagnostic     (n=179)
Chronic  abdominal pain 49(12.2)
Upper Gastrointestinal bleeding/
Portal hypertension 43(10.7)
Gastro- oesophageal reflux 30 (7.5)
Probable eosinophilic oesophagitis 17 (4.2)
Chronic diarrhoea 17(4.2)
Coeliac disease 9 (2.2)
Food allergy/CMPA/FPIES 6(1.5)
Aspiration 5 (1.2)
Cyclical vomiting 3(0.7)
(ii) Therapeutic (n=287):
Change of PEG 143(35.6)
Insertion of PEG 87 (21.6)
Sclerotherapy for varices with PHT 29 (7.2)
Band ligation for varices with PHT 28 (7.0)
(iii) Follow -up/Surveillance (n=204)
Upper gastrointestinal varices                                                                       204(50.7)
B. Combined oesphagodastroduodenoscopy &  colonoscopy (n=78)
(i) Diagnostic (n=68):
Probable inflammatory bowel disease (IBD) 30 (7.5)
Chronic diarrhoea 12 (3.0)
Abdominal tuberculosis 10(2.5)
Chronic abdominal pain 8(2.0)
Chronic iron deficiency anaemia 3 (0.7)
IBD with autoimmune hepatitis 3(0.7)
Protein losing enteropathy 2(0.5)
(ii) Follow- up/surveillance  (n=10)
Inflammatory bowel disease 10 (2.5)
C.  Colonoscopy (n = 103):
(i) Diagnostic (n=67):
Inflammatory bowel disease 30 (7.5)
Lower gastrointestinal bleeding (rectal bleeding) 26 (6.5)
Abdominal tuberculosis 9(2.2)
Bloody diarrhoea 2(0.5)
ii. Therapeutic (n=6):
Polypectomy 6 (100.0)
iii. Follow – up/Surveillance (n= 30):
Inflammatory bowel disease 30(7.5)
FPIES: Food protein induced enterocolitis; CMPA: Cow’s milk protein allergy
+Multiple entries apply in the table.
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Figure 1a, b, c: Bar charts showing the presenting symptoms among patients who had
oesophagogastroduodenoscopy, combined zesophagogastroduodenoscopy and
colonoscopy, and colonoscopy(n= 402)
+Multiple entries apply in the table.
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Figure 2a: Bar chart showing diagnostic endoscopic (oesophagogastroduodenoscopy)
yields among subjects (n= 179).
Abbreviations: GORD- Gastro oesophageal reflux disease; EOE: Eosinophilic
oesophagitis; CMV- Cytomegalo virus
35.2%
%
27.9%
17.3%
5.6%
5.0% 1.1% 0.6%
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Figure 2b: Bar chart showing diagnostic endoscopic (colonoscopy) yields among
subjects (n = 67).
Abbreviations: CMV- Cytomegalovirus; TB- Tuberculosis; PTLD- Post transplant
lymphoproliferative disorder.
37.3%
13.4%
10.4%
4.5%
3.0%
1.5%
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Appendix 1.1 Supplementary Digital Content;
Table 3:  Relationship between macroscopic  and histologic  findings in children
undergoing endoscopy
Indications: Abnormal positive histological     p-value
endoscopic finding findings
a. Upper endoscopy (n=179)
Chronic  abdominal
pain 20/49(40.8)            31/49(63.3) 0.026
Upper GI bleeding                             31/43(72.1)             4/43(9.3) <0.001
GORD*                                             8/30(26.7)               7/30(23.3) 0.766
EoE** 3/17(17.6)                3/17(17.6) NA(1.000)
Chronic diarrhoea                             11/17(64.7)              11/17(64.7) NA(1.000)
Coeliac disease                                 3/9(33.3)                   3/9(33.3) NA(1.000)
Food allergy                                     0/9(0.0)                      0/6(0.0) NA(1.000)
Aspiration                                        2/5(40)                      2/5(40) NA(1.000)
Cyclical vomiting                             1/7(33.3) 1/3(33.3) 0.490
Total                                               79/179(44.1)             62/179(34.6) 0.066
b. Combined upper and lower endoscopy(n= 68)
Probable IBD****                           18/30(60.0)              17/30(56.7) 0.069
Abdominal Tuberculosis                   4/10(40.0) 3/10(30.0) 0.639
Chronic diarrhoea                              7/12(58.3) 7/12(58.3) NA(1.000)
Chronic  abdominal pain                    3/8(37.5) 3/8(37.5) NA(1.000)
Chronic Iron deficiency anaemia 1/3(33.3) 1/3(33.3) NA(1.000)
IBD with autoimmune hepatitis        2/3(66.7) 2/3(66.7) NA(1.000)
Protein losing enteropathy ½(50.0) ½(50.0) NA(1.000)
Total                                                36/68(52.9)             34/68(50.0) 0.731
c. Lower endoscopy (n=67)
Probable IBD 19/30(63.3)                17/30(56.7) 0.598
Lower GI bleeding                        12/26(84.6)                 10/26(38.5) 0.575
Abdominal Tuberculosis               4/9(44.4) 4/9(44.4) NA(1.000)
Bloody Diarrhoea ½(50.0)                       ½(50.0) NA(1.000)
Total                                             46/67(53.7)                 32/67(47.8) 0.014
*GORD: atypical Gastro-oesophageal reflux disease,  **EoE: Eosinophilic oesophagitis,
***GI: Gastro Intestinal,    ****IBD: Inflammatory Bowel Disease
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1.2
Appendix
Supplemental Digital Content:  Table
4
Algorithm for M
edical Indicators of Oesophagogastrosduodenoscopyin Study Subjects
Presenting Symptoms
*  Feeding difficulty/poor feeding              *
Chronic epigastric pain
*  Poor weight gain or loss of weight         *
Inco–ordinate/difficulty in swallowing
*  Recurrent Aspiration
*
Chronic diarrhoea
*  Chocking with food
*
Atopy (Asthma/eczema/cough/rhinitis)
*  Chronic abdominal pain
*
Food 
Allergy 
(including 
cow 
milk 
protein
allergy)
Diagnostic Indications

Chronic abdominal pain

Upper GI bleeding/portal
hypertension

Gastro-Oesophageal Reflux
Disease(GORD)

Esoinophilic Oesophagitis

Chronic diarrhoea

Coeliac disease

Food allergy

Aspiration

Cyclical vomiting
Therapeutic indications

Insertion of PEG

Change of PEG

Sclerotherapy

Band ligation of varix/ces
Follow-up surveillance

Upper GIVarices (particularly
oesophageal varices).
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1.3
Appendix
Supplemental Digital Content:  Table5
Algorithm for M
edical Indicators of combined Oesophageogastroduodenoscopy and Colonoscopy in Study Subjects
Presenting Symptoms
*  Chronic abdominal pains
*
Persistent/Recurrent vomiting
*  Chronic diarrhoea
*
Arthritis
*  Rectal bleeding
*
Positive faecal occult blood
*  Failure to thrive
*
Food Allergy (including
cow’s milk protein
allergy)
*
Chronic Iron deficiency anaemia
*  Chronic bloody loosestools
* Chronic Constipation
Diagnostic Indications

Inflammatory bowel disease

Chronic diarrhoea

Chronic abdominal pain

Intestinaltuberculosis

Chronic iron deficiency anaemia

Protein losing enteropathy
Therapeutic indications
Follow-up surveillance

Inflammatory bowel disease
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1.4Appendix
Supplemental Digital Content: Table6
Algorithm for M
edical Indicators of Colonoscopy in Study Subjects
Presenting Symptoms

Rectal bleeding

Chronic bloody loose stools

Chronic abdominal pain

Chronic diarrhoea

Failure to thrive

Pallor/Anaemia

Arthritis
Diagnostic Indications

Inflammatory bowel disease.

Lower GI Bleeding (Rectal
bleeding/haematochezia)
Therapeutic indications

Polypectomy
Follow-up/ surveillance

Inflammatory bowel disease.

Polyps
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1.5Appendix
Study Data Collection Sheet
REVIEW
 OF M
EDICAL GI-ENDOSCOPY IN CHILDREN ATTENDING RED CROSS CHILDREN’S HOSPITAL,
CAPE TOW
N(2007-2016)
Case Record Form
Study Enrolment No.:__________
A.Socio-Demographics
Date of Birth
Age
Sex:
M
ale
Female
Address:
Native Language: (i)  (Afrikaans     (ii) English   (iii)  Xhosa    (iv)  Other (specify) ________
Socio-Economic Class
Low Social Class (H0 and HI)
M
iddle (H2)
High (H3/Private)
B.Physical Examination
Anthropometry Indices:
W
eight:_____kg
Height:_____cm
W
FA: ______z-
Score
HAZ:
BM
I Z-score:
Relevant findings on systemic examination:
(i)___________________________________________________________________________
(ii)___________________________________________________________________________
45
Relevant Radiological Reports (Diagnostic) Done:
(i)
Plain Radiograph: (ii) Fluroscopy with speech therapy (iii) Barium Studies (iv) M
ilk Scan (v) CT scan
(vi) M
RCP
(vii)
M
agnetic Resonance Enterography (M
RE)
(viii)Others (specify): _______________
C.
Clinical Characteristics:
Primary Symptoms:
(i)Poor feeding/feeding difficulty
(ii) 
Poor 
weight 
gain/failure 
to
thrive/weight loss
(iii)Bleeding per mouth/nostril/haematemesis
(iv)
Lower GIB (rectal bleeding/malaena/
haematochezia
(v)M
outh ulcers
(vi)Persistent vomiting
(vii)Chronic abdominal pain
(viii)Abdominal mass
(ix)Chronic constipation
(x)Chronic Diarrhoea
(xi)Pallor/anaemia (unexplained)
(xii)Persistent fever
(xiii)Chronic abdominal cramps/bloating
(xiv)Poor appetite
(xv)Caustic ingestion
(xvi)Odynophagia/dysphagia
(xvii)Other (specify): ________________________________________________
W
orking diagnosis prior to endoscopy: _______________________________________________________________________________
Type of Endoscopy performed:
Oesophagogastroduodenoscopy alone
Combined 
Oesophagogastroduodenoscopyoscopy
and Colonoscopy
Colonoscopy alone
46
D.
Endoscopic Variables:
Therapeutic Indications for Oesophagogastroduodenoscopy:
(i)
PEG Insertion
(v)Oesophageal sclerotherapy
(ii)Change of PEG
(vi)Oesophageal variceal banding
(iii)
PEG removal
(vii)Oesophageal non-variceal bleeding therapy (specify):
(iv)
Foreign body removal
(viii)Others (specify):
Diagnostic Indications for Oesophagogastroduodenoscopy:
(i)
Reflux oesophagitis
(v)Peptic ulcer disease (specify anatomic gastrointestinal site)
(ii)Coeliac disease
(vi)Helicobacter pylori infection
(iii)
Eosinophilic oesophagitis (EoE)/Eosinophilic gastroenteritis
(vii)Crohn’s disease
(iv)
Gastri-oesophageal refluxdisease (GORD)
(viii)Others (specify):
Interval between insertion and removal of PEG: (i) Time: …
…
…
…
…
…
…
…
…
.. (ii) NA
Therapeutic Indications for Colonoscopy:
(i)Polypectomy
(ii)Foreign body removal
(iii)Treatment of haemorrhagic lesions
(iv)Other(specify):
47
Diagnostic Indications  for Colonoscopy:
(i)Unexplained anaemia
(ii)Unexplained chronicdiarrhea
(iii)Non-specific colitis
(iv)Unexplained abdominal pain
(v)Peri-anal lesions/Proctitis/fistula
(vi)Unexplained Failure to Thrive (FTT)
(vii)Rectal blood loss
(viii)IBD (specify type):
(ix)Abdominal Tuberculosis
(x)Allergic colitis
(xi)Cytomegalovirus (CM
V) Colitis
(xii)Suspicion of graft versus host disease
(GVHD)
(xiii)Polyposis syndrome
(xiv)
Cancer surveillance
(xv)Surveillance for IBD
(xvi)Others (specify):
(xvii)Others (specify):
E.
Characteristics of gastrointestinal disorders among subjects who underwent colonoscopy:
1.
Age of onset of illness requiring colonoscopy:…
…
…
…
…
…
…
..2. Duration of illness prior to colonoscopy: …
…
…
…
…
…
..
3.
Disease activity:
(i)M
ild
(ii)M
oderate
(ii)Severe
4.
Extent of disease:
(i)Pan-colitis
(ii)Left-sided lesions
(iii)Other (specify): __________________
5.
Current use of Corticosteroids:
(i)Yes
(ii)No
6.
Current use of Immuno-modulators (Azathioprine/6-M
P):
(i)
Yes
(ii)No
7.
Current use of  Calcineurin inhibitors (e.g. Tacrolimus):
(i)
Yes
(ii)No
8.
Current use of Anti-TNF–α(Infliximab/Adalimumab): (i)  Yes
(ii)No
9.
Other immunosuppressive therapy given (specify): __________________________________
OesophagogastroduodenoscopyFindings (M
acroscopy):
(i)
Normal
(ii)Abnormal (specify):
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W
as biopsy taken during the endoscopic procedure: (i)   Yes
(ii)No   (iii)  NA
Results following endoscopic biopsy:
(i)Histology: _____________________ (ii)  Tissue culture (specify): _________________(iii) PCR (specify): ___________ (iv). NA
Colonoscopy findings:
(i)Normal
(ii)Juvenile polyps
(iii)Pan-colitis
(iv)Crohn’s disease
(v)Proctitis
(iv)Angiodysplasia
(vii)TB Colitis
(viii)Other (specify):
Final diagnosis following Endoscopy: ___________________________________________
Family history of similar illness: ________________________________________________
Source of endoscopic diagnosis:
(i)From histology
(ii)Biopsy (cultural)
(iii)PCR (specify):
(iv)Other (specify):

Is there agreement between the working diagnosis and endoscopic-enabled diagnosis:
(i)Yes  (ii)  No  (iii) NA
Complications following endoscopy:
(i)Desaturation (hypoxic event)
(ii)Arrhythmia
(v)Respiratory disease (specify):
(vii)Bleeding
(ix)Cardiac arrest
(ii)pneumoperitoneum
(iv)Gut perforation
(vi)Fistula formation (specify):
(viii)Nausea/
vomiting
(x)M
ortality
Other complication/s (specify):______________________________________
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Complications recorded during or after the procedure: (i)  Yes  (ii)  No

Did endoscopic findings aid/impacton patient’s diagnosis/M
anagement: (i) Yes  (ii) No (iii) NA
If ‘yes” to above, state the impact on management:
a.
M
edication change (specifynew medication(:
_______________________
b.
Addition of new medication/s (specify):
_______________________
c.
Change of medication (+) nutrition (specify):
_______________________
d.
Nutritional therapy (specify):
_______________________
e.
Surgery (specify):
________________________
f.
Other (specify): …
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
.
Need for repeat endoscopy: (i)
Yes
(ii)
No  (iii) NA
Indication for repeat Oesophagogastroduodenoscopy/Colonoscopy
Number of Oesophagogastroduodenoscopy done (Specify): …
…
…
…
…
…
…
…
…
…
…
…
..
Number of colonoscopy done  (Specify):…
…
…
…
…
…
…
…
…
…
…
…
..
Findings on repeat endoscopy:
(i)
M
acroscopy:
___________________________________________
(ii)
Histology:
___________________________________________
(iii)
Other (specify)
___________________________________________
(iv)
Normal
(v)
NA
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Diagnosis following repeat endoscopy:
(i)
same as before
(ii) new/change of diagnosis (iii) NA
If ‘new’ diagnosis, specify: __________________________________________
Treatment offered following repeat endoscopy (specify):…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
.
GIT Endoscopic Outcomes:
(i)Diagnosis obtained
(ii)Improved with therapeutic endoscopy
(iii)
Normal findings
(iv)
Complication following procedure
(v)Others (specify): …
…
…
…
…
…
…
…
…
M
iscellaneous (other  significant finding/s):…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
..
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Ethical and Legal Considerations
Manuscript Submission
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Manuscript Preparation
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Pre-Submission Checklist
After Acceptance
Editorial Office Contacts
SCOPE
The Journal of Pediatric Gastroenterology and Nutrition publishes original articles,
special reports, review articles, rapid communications, case reports, letters to the editor,
short communications, and commentaries on all aspects of pediatric gastroenterology,
hepatology, pancreatology, and nutrition.
The journal follows the International Committee of Medical Journal Editors' Uniform
Requirements for Manuscripts Submitted to Biomedical Journals (URM). Manuscripts
must be prepared in accordance with the URM (N Engl J Med 1997;336:309-15 and
updated at http://www.icmje.org/). Manuscripts not prepared according to the
Instructions to Authors will be returned to the author(s) without review.
ETHICAL AND LEGAL CONSIDERATIONS
A submitted manuscript must be an original contribution not previously published
(except as an abstract), must not be under consideration for publication elsewhere, and,
if accepted, it must not be published elsewhere in similar form, in any language, without
the consent of Wolters Kluwer. Each person listed as an author is expected to have
participated in the study to a significant extent. Although the editors and reviewers make
every effort to ensure the validity of published manuscripts, the final responsibility rests
with the authors, not with the Journal, its editors, or the publisher.
Documented review and approval from a formally constituted review board
(Institutional Review Board or Ethics committee) is required for all studies involving
people, medical records, and human tissues, and for all animal studies. For
authors/investigators that do not have access to formal ethics review committees, the
principles outlined in the Declaration of Helsinki should be followed. If the study is
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judged exempt from review, a statement from the committee should be provided.
Informed consent by participants should always be sought and documented in the
Methods section. If not possible, an institutional review board must decide if this is
ethically acceptable, and documentation of this decision must be included with the
submission.
Plagiarism detection
JPGN is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a
plagiarism screening service that verifies the originality of content submitted before
publication. iThenticate checks submissions against millions of published research
papers, and billions of web content. Authors, researchers and freelancers can also use
iThenticate to screen their work before submission by visiting www.ithenticate.com.
Declaration of Funding Source
ACKNOWLEDGMENT OF GRANTS OR FINANCIAL SUPPORT MUST BE
DECLARED FOR ALL MANUSCRIPTS. In addition, authors of all articles in which
the effect of a drug, appliance, or treatment is evaluated must also acknowledge all
support from the manufacturer of such drug, appliance, or treatment or its competitor.
Authors of all articles, including review articles, editorials, letters to the editor, and other
commentaries, must disclose any financial interests that might have an impact on the
views expressed in the submission. The Declaration of Funding Source statement will be
included in the published article or commentary.
The conflict of interest disclosure and funding declaration must be included on the title
page of the manuscript and in Editorial Manager. Authors with nothing to declare should
provide a statement to that effect. Manuscripts submitted without the required
disclosures will be returned to the authors.
Compliance with NIH and Other Research Funding Agency Accessibility
Requirements
A number of research funding agencies require or request authors to submit the post-
print (the article after peer review and acceptance but not the final published article) to a
repository that is accessible online by all without charge. As a service to our authors,
Wolters Kluwer will identify to the National Library of Medicine (NLM) articles that
require deposit and will transmit the post-print of an article based on research funded in
whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes
Medical Institute, or other funding agencies to PubMed Central. The Copyright Transfer
Agreement provides the mechanism.
Patient anonymity and informed consent
It is the author's responsibility to ensure that a patient's anonymity be carefully protected
and to verify that any experimental investigation with human subjects reported in the
manuscript was performed with informed consent and following all the guidelines for
experimental investigation with human subjects required by the institution(s) with which
all of the authors are affiliated.
Authors should remove patients' names and other identifying information from figures.
If any identifying details appear in text, tables, and/or figures, the author must provide
proof of informed consent obtained from the patient (i.e., a signed permission form).
Photographs with bars placed over eyes of patients should NOT be used in publication.
If they are used, permission from the patient is required.
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The corresponding author of a Case Report, Letter to Editor or Image/Video of the
Month must provide the editorial office at the time of submission of the manuscript a
written guarantee indicating that the subject(s) of the case report or their parents (or
guardians) are aware of the intent to publish and agree to it.
If the parents or guardian were unable to be located for their consent, a signed statement
from the Chair of the Department or from the Institutional Review Board may be
accepted. The statement must read: all attempts have been exhausted in trying to contact
the parents or guardian for the purpose of attaining their consent to publish the Case
Report, Letter to Editor or Image/Video of the Month.
Conflicts of Interest
Authors must state all possible conflicts of interest in the manuscript, including
financial, consultant, institutional and other relationships that might lead to bias or a
conflict of interest. If there is no conflict of interest, this should also be explicitly stated
as none declared. All sources of funding should be acknowledged in the manuscript. All
relevant conflicts of interest and sources of funding should be included on the title page
of the manuscript with the heading "Conflicts of Interest and Source of Funding:" For
example:
Conflicts of Interest and Source of Funding - A has received honoraria from Company
Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker's
bureau for Organization X – the CME organizers for Company A. For the remaining
authors, none is declared.
Copyright
In addition, each author must complete and submit the journal's copyright transfer
agreement, which includes a section on the disclosure of potential conflicts of interest
based on the recommendations of the International Committee of Medical Journal
Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals"
(www.icmje.org/update.html).
A copy of the form is made available to the submitting author during the Editorial
Manager submission process. Co-authors will automatically receive an e-mail with
instructions on completing the form upon submission.
Permissions
Authors must submit written permission from the copyright owner (usually the
publisher) to use direct quotations, tables, or illustrations that have appeared in
copyrighted form elsewhere, along with complete details about the source. Any
permission fees that might be required by the copyright owner are the responsibility of
the authors requesting use of the borrowed material, not the responsibility of Wolters
Kluwer.
Drugs, Devices, and Other Products
Use nonproprietary names of drugs, devices, and other products, unless the specific trade
name is essential to the discussion. The trade name may appear once in the Abstract and
once in the Introduction or Methods section, followed by the nonproprietary name,
manufacturer, and manufacturer location in parentheses; all other mention of the product
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must use the generic name. Trade names of drugs and other products must not appear in
the article title.
JPGN Editor Submission Policy Disclaimer:
Manuscripts submitted by the Associate Editors are subject to peer review. Manuscripts
that include an Associate Editor, one of the Editors-in-Chief, or one of the Consulting
Editors will be handled by the Consulting Editor of the alternate editorial office (with
the exception of societal papers, image/video of the month, and certain invited
submissions).
MANUSCRIPT SUBMISSION
Clicking on the submission service link on this page will open our manuscript
submission service website in a new browser window.
Submit a manuscript
First-time Users
Please click the Register button in the main menu and enter the requested information.
Upon successful registration, you will be sent an email indicating your user name and
password. Save a copy of this information for future reference. Note: If you have
received an email from us with an assigned user ID and password, or if you are a repeat
user, do not register again. Once you have an assigned ID and password, you do not
have to re-register, even if your role changes (that is, author, reviewer, or editor).
Authors please click the login button from the menu at the top of the page and log in to
the system as an Author. Submit your manuscript according to the author instructions.
You will be able to track the progress of your manuscript through the system. If you
experience any problems, please contact the appropriate Editorial Office (see below for
complete contact information) or click on the 'Contact Us' link in the header menu.
ARTICLE TYPES
Rapid Communication: This article type allows for rapid review (within 10 days) and
publication of original studies. Manuscripts considered for rapid review will be limited
to reports judged to be of general scientific or public health importance. Authors
submitting Rapid Communications must provide a detailed cover letter outlining the
rationale for fast tracking their work. Authors must state whether the findings could alter
current standards of patient care (e.g., finding efficacy or lack of efficacy of treatment),
and/or if the findings suggest a novel mechanism or understanding of disease process
(e.g., new susceptibility gene identification in H pylori organism).
Rapid Communications should contain no more than 3000 words, structured abstract
with no more than 250 words and no more than four figures and tables combined (for
example, a submission may include 4 figures, 1 figure and 3 tables, 4 tables, etc., but not
2 figures and 3 tables) and no more than 50 references. Submissions exceeding these
parameters without justification or without a detailed cover letter explaining the
rationale for a Rapid Communication will be returned to the author for correction prior
to review. Extra material such as very detailed methods, tables or figures that are not
needed by most readers may be submitted as Supplemental Digital Content without
limitation on length (see below). Articles submitted for Rapid Communication but
deemed to be more appropriate for standard submission will be returned for
resubmission as an Original Article (below).
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Original Articles: Original articles are full-length reports of original research. Original
articles are accepted based on their scientific relevance, the originality of the work, and
the priority of the work for JPGN and its readership. Authors should aim for accuracy,
clarity, and brevity. Long introductions, repetition of data among tables, figures, and the
text, and unfocused discussions should be avoided.
Original research articles should be approximately 18 double-spaced, numbered pages,
including the title page, references, figures, and tables. Failure to comply with length
restrictions may result in a delay in the processing of your paper. The following length
targets (up to 3000 words for the text including Introduction, Methods, Results and
Discussion) are recommended for Original Articles:
 Structured Abstract: maximum of 250 words
 Introduction: 1 page (about 250 words)
 Methods: 2-3 pages (up to 750-1000 words)
 Results: 2-3 pages (up to 750-1000 words)
 Discussion: 3-5 pages (up to 1000 words)
 References: limited to those critical and relevant to the manuscript (not more
than 50)
 Tables and Figures: 4 total (legends limited no more than 100 words each)
 Additional/supplemental content may be submitted as "Supplemental Digital
Content (SDC)", which has no space limitation (see section on SDC below).
Clinical Trials: Original Articles of studies that prospectively assign human subjects to
specific intervention or comparison groups and determine the relationship between an
intervention and outcome are to be submitted as "Clinical Trials". To ensure consistency
with the guidelines of the Clinical Trial Registration Statement from the International
Committee of Medical Journal Editors, all trials submitted to the Journal with patient
enrollment commencing after January 1, 2009 must be registered in a public trials
registry prior to enrollment of the first subject. The registry must incorporate free public
access, and must be searchable, open to prospective registrants, and have not-for-profit
management. The following information must be included in the registry: (1) unique
identifying number, (2) statement of intervention(s), (3) hypothesis, definition of
primary and secondary outcome measurements, eligibility criteria, target number of
subjects, funding source, contact information for principal investigator, and dates of
registration, start and completion. Authors should provide the URL (website address)
and trial identification number on the title page of the manuscript. This information will
be published with the article. The length of Clinical Trials should follow the same
guidelines as the Original Articles above (Structured Abstract (no more than 250 words);
text with no more than 3000 words; no more than 50 references permitted; no more than
4 Tables/Figures; SDC permitted). Clinical trial reports should comply with the
Consolidated Standards of Reporting Trials (CONSORT) and the checklist should be
submitted at the end of the manuscript.
Reporting Clinical Trials Conducted by Pharmaceutical Companies: Please ensure
that clinical trials sponsored by pharmaceutical companies follow the guidelines on
Good Publication Practice. These guidelines aim to ensure that such trials are published
in a responsible and ethical manner. The guidelines cover companies' responsibility to
endeavor to publish results of all studies, companies' relations with investigators,
measures to prevent redundant or premature publication, methods to improve trial
identification, and the role of professional medical writers.
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STAndards for the Reporting of Diagnostic accuracy studies (STARD checklist): If
you are reporting a study that has assessed one or more diagnostic tests you must
complete the STARD Statement, and paste it onto the end of your full manuscript.
STrengthening the Reporting of OBservational studies in Epidemiology (STROBE
Statement): Reports of an observational cohort, case-control, or cross-sectional study
must include the relevant STROBE Checklist at the end of the manuscript. Additional
information can be found on the STROBE website.
Standards for QUality Improvement Reporting Excellence (SQUIRE statement)
should be applied for quality improvement (QI) projects and those involving a detailed
consensus process.
Review Articles: Review articles are usually solicited by the Editorial Board. However,
unsolicited reviews of exceptional interest will also be considered. Authors should
contact the Editors before submitting a review to determine whether the topic and
contents are appropriate for JPGN. All proposed reviews will be approved based on a
submitted list of author(s) and a brief outline for the proposed review. Reviews should
be balanced and unbiased. Review articles undergo peer review. While we allow some
flexibility for Review Articles, authors should aim to follow the same guidelines as the
Original Articles above (exception being an Unstructured Abstract of no more than 250
words): text with no more than 3000 words; no more than 50 references permitted; no
more than 4 Tables/Figures; SDC permitted). Authors submitting longer Review
Articles must justify the length in the cover letter.
For Systematic reviews/Meta-analyses, please follow the guidelines listed above, but
please include a structured abstract of no more than 250 words. A Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist should be
included at the end of the manuscript. Alternatively, the MOOSE checklist should be
applied for meta-analyses of observational studies.
A full list and index of reporting guidelines can be found at www.equator-
network.org/library/. All can be downloaded as Word documents that can then be
included at the end of the manuscript.
Short Communications: This category comprises brief reports on topics relevant to the
JPGN reader and preliminary reports of original studies of relevant scientific
importance. Short Communications must not exceed 2000 words. Include an
unstructured abstract of 150 words or less. Short Communications should contain no
more than 2 tables and/or figures, and no more than 20 references are permitted.
Invited Commentary: These submissions are typically no more than 500-1000 words
in length and are usually considered by invitation only. Requests to submit a
commentary regarding a 'hot topic' should be made to one of the editors. Generally no
more than 5-10 references, and 1 table and/or 1 figure are permitted. No abstract needed.
Topic of the Month: These submissions are typically no more than 1000-1500 words in
length and are usually considered by invitation only. An unstructured abstract should be
no more than 150 words. References should be limited to those critical and relevant to
the manuscript. No more than 30 references and a total of 2 figures and/or tables.
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Societal Papers: These submissions are coordinated by ESPGHAN and/or
NASPGHAN. For more information about submitting a societal paper, please contact
the ESPGHAN or NASPGHAN Consulting Editor for Societal Papers. An abstract of no
more than 250 words, is optional and can be structured or unstructured.
ONLINE ONLY ARTICLE TYPES
The JPGN is transitioning to increasing the number of articles as online only. The
Editors of JPGN now select some high impact and special feature articles for online only
publication, particularly those with basic scientific merit. These articles appear in all
electronic version of the journal in the next issue available after receipt of material
required for publication. The corresponding print issue will include the article in the
Table of Contents, and will publish the article abstract. Articles are typeset in standard
journal format, and the corresponding author will be emailed a PDF of the article on
publication. Authors will usually be informed about the decision for this modality at the
time of final acceptance.
All Case Reports, Image of the Month, Video of the Month, and Letters to the
Editor will be reviewed and accepted as online only content. Papers in these sections
will still be assigned to an issue and listed in the issue's Table of Contents, and will
appear in full on the journal website and in all electronic versions of the journal.
Case Reports (online only): Only exceptional cases will be accepted by the JPGN as
case reports; thus, the report should present unique case(s) that are deemed important to
the health of our patients or the advancement of the knowledge base in our field. It is
helpful if you submit a Case Report to please include in your cover letter a brief
paragraph that explains why your case meets the above criteria. Alternately, you may
submit your report as a Letter to Editor; Letters may include up to one figure or table.
Case Reports will be considered for publication only if they concern a hitherto
unrecognized condition or offer new insight into the pathophysiology, diagnosis, or
treatment of a disease. Patients should always be referred to as "the patient"; initials or
other identification should not be used. Case Reports must not exceed 1,000 words, and
may include up to three tables and/or figures, and no more than 8 references. An abstract
is not required, and if present, it will be included in the word count.
Image of the Month (online only): Submissions for the "Image of the Month" should
include one (at most two) high quality TIF endoscopic, histologic, radiologic, or
photographic images of unusual or informative findings. A brief description of no more
than 200 words should accompany the images. No more than 8 references permitted. No
abstract.
Video of the Month (online only): Submissions for the "Video of the Month" should
include high quality endoscopic video of unusual or informative findings. One or two
additional associated photos, such as radiologic, pathologic, or photographic images, can
also be submitted for online publication. A brief description of no more than 200 words
should accompany the video. No more than 8 references permitted. No abstract. Videos
should be uploaded as Supplemental Digital Content with one of the following file
extensions: .wmv, .mov, .qt, .mpg, .mpeg, .mp4; and formatted with a 320 x 240 pixel
minimum screen size. For more information, please review Wolters Kluwer's
requirements for submitting supplemental digital content: http://links.lww.com/A142.
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Letters to the Editor (online only): A Letter to the Editor may be in response to an
article published in JPGN or may comment on a controversial issue. Letters should be
brief (no more than 250 words), and will be published at the discretion of the editor. No
abstract.
Filler material (in print only): Material such as historical vignettes, photographs, or
brief poems/stories/comments may be submitted as 'filler' material that are inserted by
the publisher into extra space as available. "Filler" space is available when a paper does
not fill at least 50% of the last page in the proofs of the paper. "Fillers" are accepted at
the discretion of the Editors in Chief. table
Summary of Article Type Parameters
Article Type Abstract
What is New/
What is
Known
Text
Limit
Figure/Table
Limit Reference Limit
Rapid
Communication
Structured
250 words Yes
3000
words 4 50
Original Articles Structured250 words Yes
3000
words 4 50
Clinical Trials Structured250 words Yes
3000
words 4 50
Systematic
reviews /
Meta-analyses
Structured
250 words Yes
3000
words 4 50
Review Articles Unstructured250 words Yes
3000
words 4 50
Short
Communications
Unstructured
150 words Yes
2000
words 2 20
Invited
Commentary None Not required
1000
words 1 10
Topic of the
Month
Unstructured
150 words
Yes (for social
media only)
1500
words 2 30
Societal Papers Optional250 words
Yes (for social
media only) n/a n/a n/a
Online Only Article Types
Case Reports* None Not required 1000words 3 8
Image of the None Not required 200 2 8
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Month words
Video of the
Month None Not required
200
words 2 8
Letters to the
Editor and
Response
None Not required 250words 1 8
MANUSCRIPT PREPARATION
Manuscripts that do not adhere to the preceding guidelines and following instructions
will be returned to the corresponding author for technical revision before undergoing
peer review. Concise, clearly written articles are more likely to be accepted for
publication in the Journal of Pediatric Gastroenterology and Nutrition. Authors whose
first language is not English are STRONGLY encouraged to ask a native English-
speaking colleague or a professional author's editor, preferably with knowledge in the
subject matter contained in the manuscript, to edit their manuscript before submission. A
list of editing services is available at
http://journals.lww.com/jpgn/_layouts/1033/oaks.journals/editservices.aspx.
Cover Letter: In the cover letter provide a statement as to whether the paper was
previously published in any language, including the abstract and whether the paper is
currently under consideration elsewhere for publication.
Title page: Include on the title page (a) complete manuscript title; (b) authors' full
names, in order from first to last authors; state first name (given name) then last name
(family name), highest academic degrees, and affiliations; (c) name and address for
correspondence, including fax number, telephone number, and email address; (d)
address for reprints if different from that of corresponding author; (e) all sources of
support, including pharmaceutical and industry support, that require acknowledgment;
(f) the URL (website address) and trial identification number; (g) disclosure of funding
received for this work from any of the following organizations: National Institutes of
Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and
other(s); and (h) the word count of the manuscript body (excluding abstract except in
Case Reports, keywords, references and figure legends), number of figures and number
of tables.
All relevant conflicts of interest and sources of funding must also be included on the title
page of the manuscript with the heading "Conflicts of Interest and Source of Funding."
If there is no conflict of interest, this should also be explicitly stated as none declared.
On a separate page, list each author and his/her respective roles in the submitted work,
documenting appropriate input for authorship
(http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-
role-of-authors-and-contributors.html#two).
Title length: The manuscript title should have no more than 120 characters including
spaces. Keywords for referencing should be included in the title. Please no
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abbreviations. Fancy or comical titles are inappropriate and will be asked to be revised.
Trade names of drugs and other products must not appear in the article title.
Structured abstract and key words: Please refer to the table above for abstract
requirements for various article types. Do not cite references in the abstract. Limit the
use of abbreviations and acronyms. At first mention, please write out the full term for
abbreviations (e.g. Celiac Disease (CD)). Use the following subheads in your structured
abstract: Objectives, Methods, Results, and Conclusions.
For Keywords, list three to five key words that are not included in the title.
What is Known/What is New: Immediately following the abstract (in the manuscript
WORD file) for all article types except where indicated in chart above, authors should
include text for a summary box that will be published on the first page of all accepted
articles. This text should highlight the significance of the article with the following
guidelines in mind: What is known about this subject? What are the new findings and/or
what is the impact on clinical practice? Use the format:
 What is known (2-4 bullet points listed beneath this heading)
 What is new (2-4 bullet points listed beneath this heading)
The total text should not exceed 100 words. As this section should be able to stand
alone, at first mention of an abbreviation, please write out the full term.
Text: Organize the manuscript into four main headings: Introduction, Methods, Results,
and Discussion. If a brand name is cited, supply the manufacturer's name and address
(city and state/country). Under Methods, include ethical approval information, if
applicable.
Data Analysis: Description of data analyses should provide the specific methods used,
their rationale, their assumptions, whether data met those assumptions, and how any
missing data were handled. Try to include confidence intervals rather than or with p-
values as appropriate.
Abbreviations: For a list of standard abbreviations, consult the Council of Biology
Editors Style Guide (available from the Council of Science Editors, 9650 Rockville
Pike, Bethesda, MD 20814) or other standard sources. Write out the full term for each
abbreviation at its first use in abstract, what is known, manuscript body and in each table
and figure unless it is a standard unit of measure.
References: Please adhere to the reference limits noted for each article type above. The
authors are responsible for the accuracy of the references. Key the references (double-
spaced) at the end of the manuscript. Cite the references in text in the order of
appearance. Cite unpublished data—such as papers submitted but not yet accepted for
publication and personal communications, including email communications—in
parentheses in the text. If there are more than three authors, name only the first three
authors and then use et al. Refer to the List of Journals Indexed in Index Medicus for
abbreviations of journal names, or access the list at
http://www.nlm.nih.gov/tsd/serials/lji.html.
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Sample references:
Journal article
I. Rautava S, Lu L, Nanthakumar NN, et al. TGF-β2 induces maturation of immature
human intestinal epithelial cells and inhibits inflammatory cytokine responses induced
via the NF-κB pathway. J Pediatr Gastroenterol Nutr 2012;54:630-8.
Book chapter
2. Todd VR. Visual information analysis: frame of reference for visual perception. In:
Kramer P, Hinojosa J, eds. Frames of Reference for Pediatric Occupational Therapy.
Philadelphia: Lippincott Williams & Wilkins; 1999:205–56.
Entire Book
3. Ming S-C, Goldman H. Pathology of the Gastrointestinal Tract. Philadelphia:
Lippincott Williams & Wilkins; 1998.
Software
4. Epi Info [computer program]. Version 6. Atlanta: Centers for Disease Control and
Prevention; 1994.
Online journals
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol
[serial online] January 1988;71: 22-37. Available from: BRS Information Technologies,
McLean, VA. Accessed December 15, 1990.
Database
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute;
1996. Updated March 29, 1996.
World Wide Web
7. Sullivan D. Major search engines and directories. SearchEngineWatch Web site.
http://www.searchenginewatch.com/links/article.php/2156221. Published May 8, 2011.
Accessed July 13, 2012.
Figure legends: Each figure must have a legend. Legends should be brief (no more than
100 words) and should be typed on a separate manuscript page, directly following the
reference list. Use scale markers in the image for electron micrographs, and indicate the
type of stain used. Please let the editors and reviewers know if any of the figures (e.g.,
figures of study design) are appropriate for the on-line supplemental digital content
(SDC) rather than needing to be in-print version.
Figures:
A) Creating Digital Artwork
 Learn about the publication requirements for Digital Artwork:
http://links.lww.com/ES/A42
 Create, Scan and Save your artwork and compare your final figure to the Digital
Artwork Guideline Checklist (below).
 Upload each figure to Editorial Manager in conjunction with your manuscript
text and tables.
B) Digital Artwork Guideline Checklist
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 Artwork should be saved in TIFF, Word Doc, PPT or EPS format (PDF is not
recommended).
 Artwork is created as the actual size (or slightly larger) it will appear in the
journal. (To get an idea of the size images should be when they print, study a
copy of the journal to which you wish to submit. Measure the artwork typically
shown and scale your image to match.)
 Crop out any white or black space surrounding the image.
 Diagrams, drawings, graphs, and other line art must be vector or saved at a
resolution of at least 1200 dpi.
 Photographs, radiographs and other halftone images must be saved at a
resolution of at least 300 dpi.
 Photographs and radiographs with text must be saved as postscript or at a
resolution of at least 600 dpi.
 Each figure must be saved and submitted as a separate file. Figures should not be
embedded in the manuscript text file.
C) Remember:
 Cite figures consecutively in your manuscript.
 Number figures in the figure legend in the order in which they are discussed.
 Upload figures consecutively to the Editorial Manager web site and number
figures consecutively in the Description box during upload.
Tables: Cite tables consecutively in the text and number them in that order. Each table
should be submitted as a separate Word document in text format. Each table must have a
title. Use footnotes to define abbreviations and for other explanatory detail in a legend
below the Tables. Tables should be self-explanatory and must supplement, rather than
duplicate, the material in the text. Please let the editors and reviewers know if any of the
tables (e.g., large data tables, large demographic tables, etc.) are appropriate for the on-
line supplemental digital content (SDC) rather than needing to be in-print version.
Supplemental Digital Content (SDC): Authors may submit supplemental digital
content with a submission to enhance their article's text or include text, tables, and
figures outside of the specified limits. All supplemental digital content is posted online
only. One advantage of including material as SDC is that SDC has no limitation of space
or length. SDC may include the following types of content: text documents including
very detailed methods, graphs, tables, figures, graphics, illustrations, audio, and video.
Authors are encourages to submit related but not essential tables (e.g., large tables of
articles cited in a meta-analysis, or a large demographic table of a study population) as
SDC.
Notes: All online-only materials will be subject to peer review and published at the
Editor-in-Chief's discretion. SDC text will not be copyedited. Submit contente exactly as
intended to be displayed (including legends). No errata will be written for SDC content.
No patient-identifying information should be used in SDC unless written consent from
the patient, the patient's parents or the patient's guardian has been obtained.
Documentation regarding this consent must be submitted with the manuscript. Copyright
and Permission forms for article content including SDC must be provided at the time of
submission.
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Guidelines for Submitting Supplemental Digital Content (SDC):
 Each piece of supplemental content should be uploaded in a separate file
 Cite all supplementary content consecutively in the text and independently from
any figures or tables.
 All Online-only Materials, no matter the type, should be listed and labeled
consecutively "Supplemental Digital Content"
o Example of separate numbering for all SD Content:
 Video, Supplemental Digital Content 1
 Table, Supplemental Digital Content 2
 Figure, Supplemental Digital Content 3
o Meanwhile, you will still have Figure 1, Figure 2, Table 1, Table 2, etc.
 Citations should include the type of material submitted, be clearly labeled as
"Supplemental Digital Content," include a sequential number, and provide a brief
description of the supplementary content.
o Example of a citation within text: (See Video, Supplemental Digital
Content 1, which demonstrates the degrees of flexibility in the elbow)
 Provide a separate legend of online supplementary materials at the end of the
text. List each item in the order in which the material is cited in the text. The
legends must be numbered to match the citations from the text.
Supplemental Digital Content Size & File Type Requirements: To ensure a quality
experience for those viewing supplemental digital content, it is suggested that authors
submit supplemental digital files no larger than 10 MB each. Documents, graphs, and
tables may be presented in any format. Figures, graphics, and illustrations should be
submitted with the following file extensions: .tif, .eps, .ppt, .jpg, .pdf, .gif. Audio files
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